Amsterdam, May 9, 2013 - New engineered spider protein could be the start of a new generation of anti-venom vaccines, potentially saving thousands of lives worldwide. The new protein, created from parts of a toxin from the reaper spider, is described today in the Elsevier journal Vaccine.
The researchers behind the study, from the Universidade Federal de Minas Gerais in Brazil, say that the engineered protein may be a promising candidate for developing therapeutic serums or vaccines against other venoms.
Reaper spiders, or brown spiders, are a family of species found all over the world that produce harmful venoms. The toxic bite of these spiders causes skin around the bite to die, and can lead to more serious effects like kidney failure and haemorrhaging. These Loxosceles spiders are most prevalent in Brazil, where they cause almost 7,000 human accidents every year.
The new study describes an engineered protein made of three pieces of a venom toxin from the Loxosceles intermedia spider. The engineered protein is not itself toxic, and gives effective protection against the effects of the pure spider venom in animal models.
"In Brazil we see thousands of cases of people being bitten by Loxosceles spiders, and the bites can have very serious side-effects," said Dr. Chávez-Olortegui, corresponding author of the study. "Existing anti-venoms are made of the pure toxins and can be harmful to people who take them. We wanted to develop a new way of protecting people from the effects of these spider bites, without having to suffer from side-effects."
Current approaches to protecting against venom involve giving the venom to animals, and taking the resulting antibodies for the serum. These antibodies enable the human immune system to prepare to neutralize venom from bites. Although they are somewhat effective, the production of anti-venoms like these is problematic because animals are required to produce them, and these animals suffer from the effects of the venom.
The new protein is engineered in the lab, without the need for the venomous animals. It is made up of three proteins, so it can protect against more than one kind of toxin at a time. The protein is not harmful to the immunized animal that produces the antibodies. It is also more effective than existing approaches, and easier to produce than preparing crude venom from spiders.
"It's not easy taking venom from a spider, a snake or any other kind of venomous animal," said Chávez-Olortegui. "With our new method, we would be able to engineer the proteins in the lab without having to isolate whole toxins from venom. This makes the whole process much safer."
The researchers tested their new protein on rabbits: all immunized animals showed an immune response similar to the way they respond to the whole toxin. The engineered protein was effective for venom of the L. intermedia and L. gaucho sub-species, which have similar toxins. Immunized rabbits were protected from skin damage at the site of venom injection, and from haemorrhaging.
This engineered protein may be a promising candidate for therapeutic serum development or vaccination in the future.
Notes for Editors
"Generation and characterization 1 of a recombinant chimeric protein (rCpLi) consisting of B-cell epitopes of a dermonecrotic protein from Loxosceles intermedia spider venom" by T. M. Mendes, D. Oliveira, L. Minozzo, R. Machado de Avila, C. Duarte, C. Dias-Lopes, G. Guimarães, L. Felicori, J. C. Minozzo, C. Chávez-Olortegui [DOI: http://dx.doi.org/10.1016/j.vaccine.2013.03.048] Vaccine, published by Elsevier.
Full text of this article is available to credentialed journalists upon request; contact firstname.lastname@example.org or +31 20 485 3564 to obtain copies of the paper or to set up interviews with the authors.
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society, The International Society for Vaccines and The Japanese Society for Vaccinology. http://www.elsevier.com/locate/vaccine
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.